NYSE: HIMS

Hims & Hers Health (HIMS) Stock Analysis & Forecast

Nov 13 close

$19.730.00 (0.0%)

Gekko Brief

AI summaryNov 9 close

Hims & Hers Health slid this week after third-quarter 2026 results missed Wall Street's expectations on both revenue and earnings, compared with earnings of $0.06 per share a year ago. The company also narrowed its full-year revenue outlook as margins contracted, citing lower-than-expected third-quarter sales. Separately, Andrew Huberman was appointed to the company's Board of Directors, a move framed around his standing as a health and wellness commentator.

The stock closes at $22.94, down 11.8% on the day, with its close sitting between the 50-day average of $28.31 and the 200-day average of $26.87, pointing to a mixed trend. Returns over one, three and six months stand at -25.8%, -24.8% and -21.3% respectively, with a one-year return of -44.7%. The GekkoIndex reads 68.8, placing HIMS in the Accumulation zone, up 5.1 over five days. Price sits 51.3% below the Gekko Fair Value of $47.14.

No confirmed earnings date appears on the calendar following the 10 August 2026 report, so the next 20 trading days carry no scheduled print. Options activity shows 5 unusual signals over the past 30 days, with call premium of $8,330,191 against put premium of $2,819,157. Analyst consensus across 14 firms stands at 3 buy and 11 hold ratings, with a consensus target of $31.15. Seasonally, the next 20 trading days from this point have averaged +15.4% across 5 years, rising in 3 of them, a pattern worth noting given the stock's typical 20-day move of 15.9%.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Hims & Hers Health price vs fair value

$39.21$19.73Nov ’25May ’26Nov ’26
Close $19.73200-day averageGekko Fair Value $39.21

Hims & Hers Health quick facts

Market cap
$4.44B
P/E ratio
—
Forward P/E
54.1
EPS, TTM
−$0.83
Revenue, TTM
$2.87B
Profit margin
-6.6%
Dividend yield
—
Beta
2.50
Volume
9.97M avg 14.97M
1-year return
−49.4%
Typical daily move
±11.9%
Typical 20-day move
±16.1%
50-day average
$27.61
200-day average
$26.68
Next earnings
Feb 22 after close
Shares outstanding
226.0M
52-week range
$13.74$40.99

Hims & Hers Health swing-trade checklist

Hims & Hers Health scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive1 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $19.73 sits between the 50-day ($27.61) and 200-day ($26.68) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    71.8, Buying

    Reading 71.8 is in the Buying zone.

    See the GekkoIndex
  • Fair valuesupportive

    49.7% below

    Price is 49.7% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 7 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 99 days

    Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.8% on average

    From this point in the calendar, the next 20 trading days averaged +2.8% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Hims & Hers Health stock chart and price history

Hims & Hers Health closed at $19.73 on Nov 13, 2026, −49.4% over the past year, inside a 52-week range of $13.74 to $40.99.

Close50-day average200-day averageVolume
Hims & Hers Health share price, past year, with 50-day and 200-day moving averages and volume$30$40$50DecJan 2026FebMarAprMayJunJulAugSepOctNov19.73

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−32.8%
3 months
−31.0%
6 months
−21.2%
1 year
−49.4%
The full HIMS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HIMS in Gekko

Follow Hims & Hers Health through every session

Put HIMS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track HIMS in GekkoFree for 7 days. No credit card required.

About Hims & Hers Health

Hims & Hers Health runs an online service that pairs customers with licensed clinicians for remote visits and follow-up care, reachable through its websites and a mobile app. It is recognized for bringing both prescription and everyday health items straight to consumers, with particular attention paid to wellness, sexual health, skincare, and hair care needs.

Customers can order ongoing prescription treatments as well as a range of over-the-counter goods, among them vitamin C, melatonin, biotin, and collagen protein supplements for general wellness, moisturizers, serums, and face washes for skin care, condoms, delay sprays, vibrators, and lubricants for sexual health, and shampoos, conditioners, scalp scrubs, and minoxidil treatments for hair care. The company also places some of its products with other sellers through wholesale deals, in addition to its direct-to-consumer sales.

Hims & Hers Health is based in San Francisco, California. Its stock trades on the NYSE under the ticker HIMS.

Listed
NYSE
Sector
Health services
Industry
Medical/Nursing services
Website
hims.com

Hims & Hers Health GekkoIndex: the smart money zone

Hims & Hers Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.8, in the Buying zone, up 8.6 points over five sessions.

010071.8Buying

Up 8.6 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying (current zone)46−2.5%+2.9%+10.3%+37.9%
Accumulation220+1.6%+3.6%+13.3%+18.4%
Neutral371+1.9%+2.9%+5.1%+11.5%
Distribution54+4.9%+8.0%+4.7%+4.4%
Selling11−0.1%+14.0%−3.2%−4.7%

Average HIMS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.

Buying zone: Smart money likely accumulating heavily. About the five zones →

See every daily GekkoIndex reading plotted over the HIMS price, zone by zone.Track HIMS in Gekko

Is Hims & Hers Health stock overvalued? Gekko Fair Value

Hims & Hers Health trades 49.7% below Gekko Fair Value of $39.21, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Hims & Hers Health shares are worth, recalculated every trading day.

$39.21

Gekko Fair Value, Nov 14, 2026

49.7% Undervalued

At the end of Aug 2026 the price was 6.1% below the estimate.

Gekko Fair ValueShare price, month end
$39$20Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open HIMS in Gekko

Hims & Hers Health insider and Congress trading

No open-market insider purchases were filed for Hims & Hers Health, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for HIMS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every HIMS insider filing, plotted on the chart in Gekko.Open HIMS in Gekko

Congress trades last 90 days

No trades in HIMS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for HIMS, plotted on the chart in Gekko.Open HIMS in Gekko

Buybacks

Hims & Hers Health has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$23.07M
As a share of market cap
0.52%

From company filings.

Unusual options activity last 30 days

7signals, 75% of the flagged premium in calls.

Latest: Bullish flow on Nov 13, $277K in unusual premium.

Hedge funds and billionaires quarter ended Sep 30

3of the funds Gekko tracks hold HIMS.

0added2opened1trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Hims & Hers Health earnings: next date and track record

Hims & Hers Health reports on Feb 22, 2027, after the close (99 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±12.5%average move across the report
1 of 8reports followed by a gain

Share-price move across each report

−19.1%Feb ’25+21.2%May ’25−11.2%Aug ’25−5.9%Nov ’25−1.1%Feb ’26−11.5%May ’26−3.4%Aug ’26−26.4%Nov ’26

Last earnings call, Nov 9, 2026 AI summary

What they said
Hims & Hers reported Q3 2026 revenue growth accelerating to nearly 50%, with nearly 3 million customers across 4 continents. The company highlighted its integrated platform model combining pharmacy infrastructure, AI technology, and direct consumer relationships. Strategic moves include partnerships with Novo and Lilly, board addition of Andrew Huberman, launch of testosterone replacement therapy, and an upcoming Peptides Plus offering.
Guidance
Management deliberately reduced weight loss marketing spend to reposition for 2027, signaling near-term investment headwinds. No specific revenue or earnings targets were provided in this excerpt, but aggressive investment across metabolic health, global expansion, and category growth was emphasized.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 9, 2026−$0.14
est $0.06
−348.8%$890.4M
est $893.1M
−0.3%−26.4%
Aug 10, 2026−$0.10
est −$0.07
−42.9%$753.2M
est $698.9M
+7.8%−3.4%
May 11, 2026−$0.40
est $0.13
−396.7%$608.1M
est $616.8M
−1.4%−11.5%
Feb 23, 2026$0.07
est $0.02
+250.0%$617.8M
est $619.2M
−0.2%−1.1%
Nov 3, 2025$0.06
est $0.09
−33.3%$599.0M
est $618.1M
−3.1%−5.9%
Aug 4, 2025$0.17
est $0.18
−5.6%$544.8M
est $584.1M
−6.7%−11.2%
May 5, 2025$0.20
est $0.12
+65.4%$586.0M
est $538.6M
+8.8%+21.2%
Feb 24, 2025$0.11
est $0.22
−49.4%$481.1M
est $494.6M
−2.7%−19.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Hims & Hers Health stock forecast and analyst price targets

Analysts’ average 12-month price target for Hims & Hers Health is $28.31, +43.5% from the last close, from 12 firms rating the stock in the last 90 days.

$28.31consensus 12-month target, +43.5% from the last close
Low $24High $40
Buy3
Hold9
Sell0

Each firm’s latest rating in the last 90 days: 12 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11KeyBancHold, maintained——
Nov 10NeedhamBuy, reiterated$32+62.2%
Nov 10Morgan StanleyHold, reiterated$25+26.7%
Nov 10Leerink PartnersHold, maintained$24+21.6%
Nov 10J.P. MorganHold, maintained$24+21.6%
+10.3%average 20-day move after past Buying readings
+2.8%average move over the next 20 trading days in the last 5 years
±11.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Hims & Hers Health seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Hims & Hers Health averaged +2.8% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−32.7%2021+21.9%2022+17.9%2023+44.0%2024−2.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−7.8%1 of 5
Next 10 trading days+1.4%3 of 5
Next 15 trading days+5.8%4 of 5
Next 20 trading days+2.8%3 of 5
Next 30 trading days−3.0%2 of 5

For scale, HIMS’s typical 20-trading-day move in either direction is about 16.1%.

Hims & Hers Health market cap and key statistics

Hims & Hers Health’s market cap is $4.44B and revenue of $2.87B over the last twelve months.

Valuation

Market cap
$4.44B
Forward P/E
54.1
EPS, TTM
−$0.83
Gekko Fair Value
$39.21

Trading

Volume
9.97M
Avg volume, 20 days
14.97M
52-week high
$40.99
52-week low
$13.74
Shares outstanding
226.0M

Financials

Revenue, TTM
$2.87B
Profit margin
-6.6%
Return on equity
-40.8%
Quarterly earnings growth, YoY
−17.4%

Risk and income

Beta
2.50
Typical daily move
±11.9%
Typical 20-day move
±16.1%

Hims & Hers Health stock news this week

Coverage of Hims & Hers Health this week reads negative: 1 positive, 0 neutral and 2 negative headlines.

News sentiment negative

Hims & Hers Health peers

Hims & Hers Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
GHGuardant Health−2.8%Accumulation16.4% below
SOLVSolventum0.0%Neutral17.0% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
EHCEncompass Health−0.4%Neutral14.7% above
ENSGEnsign+0.3%Neutral15.6% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

Hims & Hers Health stock FAQ

What is Hims & Hers Health’s market cap?

Hims & Hers Health’s market cap is $4.44B at the Nov 13, 2026 close of $19.73, with 226.0M shares outstanding.

What is the Hims & Hers Health stock forecast?

The consensus analyst 12-month price target for Hims & Hers Health is $28.31, +43.5% from the last close. Of the 12 firms that rated the stock in the last 90 days, 3 rate it a buy, 9 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Hims & Hers Health stock overvalued or undervalued?

On Gekko’s estimate Hims & Hers Health is undervalued: the Nov 13, 2026 close of $19.73 is 49.7% below Gekko Fair Value of $39.21. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Hims & Hers Health report earnings next?

Hims & Hers Health is expected to report on Feb 22, 2027, after the market closes (99 days away). Analysts expect earnings of $0.02 per share on revenue of $903.1M. Hims & Hers Health beat the earnings estimate in 2 of its last 8 reports, moving 12.5% on average across the report.

What is Hims & Hers Health’s 52-week high and low?

Hims & Hers Health’s 52-week high is $40.99 and its 52-week low is $13.74; it closed at $19.73 on Nov 13, 2026, −49.4% over the past year. Over the last five years the shares peaked at $72.98 on Feb 19, 2025.

Is Hims & Hers Health stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Hims & Hers Health?

Gekko flagged 7 unusual options signals in Hims & Hers Health over the last 30 days, with $8.84M of flagged premium in calls and $2.95M in puts. The latest, bullish flow, was on Nov 13, 2026 with $277K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Hims & Hers Health the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.